Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Factors to Note Ahead of Hewlett Packard (HPE) Q1 Earnings

by Zacks Equity Research

Hewlett Packard's (HPE) fiscal first-quarter results are likely to reflect gains from growing demand for its cloud services amid the ongoing digital transformation trend.

Tirthankar Chakraborty headshot

3 Top Profitable Stocks to Buy on Solid Net Income Ratio

by Tirthankar Chakraborty

Lamb Weston (LW), Catalyst Pharmaceuticals (CPRX) and Northeast Community Bancorp (NECB) are some of the top picks with a high net income ratio.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.38, moving +0.79% from the previous trading session.

Zacks Equity Research

Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Catalyst Pharmaceuticals, Inc. (CPRX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Factors to Note Ahead of Zscaler's (ZS) Q2 Earnings Release

by Zacks Equity Research

The increased demand for security and networking products amid the ongoing hybrid work environment and digitization process is likely to have aided Zscaler's (ZS) second-quarter performance.

Zacks Equity Research

Is Catalyst (CPRX) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.

Zacks Equity Research

Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.